Spero Therapeutics (SPRO) EPS (Basic) Growth (3y) (2019 - 2026)
Spero Therapeutics (SPRO) EPS (Basic) Growth (3y) (2019 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 6.85% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 11.71% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 64.84% |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 18.44% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 37.21% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 36.73% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 67.51% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | -38.31% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -26.87% |
| 10 | Spero Therapeutics | 70.14 Mn | 19.37 Mn | - | 10.07% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 9.54% |
| Mar 31, 2026 | 20.08% |
| Dec 31, 2025 | 30.31% |
| Sep 30, 2025 | -14.31% |
| Jun 30, 2025 | -34.45% |
| Mar 31, 2025 | 37.89% |
| Dec 31, 2024 | 14.38% |
| Sep 30, 2024 | 43.93% |
| Jun 30, 2024 | 35.22% |
| Mar 31, 2024 | 44.23% |
| Dec 31, 2023 | -10.49% |
| Sep 30, 2023 | 64.35% |
| Jun 30, 2023 | 49.73% |
| Mar 31, 2023 | 45.10% |
| Dec 31, 2022 | -19.56% |
| Sep 30, 2022 | 36.48% |
| Jun 30, 2022 | 2.88% |
| Mar 31, 2022 | -44.32% |
| Dec 31, 2021 | -85.18% |
| Sep 30, 2021 | -42.54% |